Invex Therapeutics Ltd (IXC.AX)
AUD 0.07
(-10.67%)
AUD 0.07
(-10.67%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 1.21 Million AUD | 164.06% |
| 2023 | 459.08 Thousand AUD | 151.9% |
| 2022 | 182.25 Thousand AUD | 0.0% |
| 2021 | - AUD | 0.0% |
| 2020 | - AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 FY | - AUD | -100.0% |
| 2024 Q2 | - AUD | 0.0% |
| 2024 Q4 | 1.21 Million AUD | 0.0% |
| 2023 Q3 | 229.54 Thousand AUD | -48.64% |
| 2023 FY | 459.08 Thousand AUD | 151.9% |
| 2023 Q4 | 459.08 Thousand AUD | 100.0% |
| 2023 Q2 | 446.91 Thousand AUD | 0.0% |
| 2023 Q1 | - AUD | -100.0% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 Q1 | - AUD | 0.0% |
| 2022 FY | 182.25 Thousand AUD | 0.0% |
| 2022 Q4 | 182.25 Thousand AUD | 100.0% |
| 2022 Q3 | 91.12 Thousand AUD | 0.0% |
| 2021 FY | - AUD | 0.0% |
| 2021 Q1 | - AUD | 0.0% |
| 2021 Q4 | - AUD | 0.0% |
| 2021 Q3 | - AUD | 0.0% |
| 2021 Q2 | - AUD | 0.0% |
| 2020 FY | - AUD | 0.0% |
| 2020 Q4 | - AUD | 0.0% |
| 2020 Q3 | - AUD | 0.0% |
| 2020 Q2 | - AUD | 0.0% |
| 2020 Q1 | - AUD | 0.0% |
| 2019 Q3 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 66.44 Million AUD | 98.176% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 94.95 Thousand AUD | -1176.704% |
| Biome Australia Limited | 13 Million AUD | 90.681% |
| Patrys Limited | 1.39 Million AUD | 13.048% |
| Orthocell Limited | 5.31 Million AUD | 77.193% |
| Imugene Limited | - AUD | -Infinity% |
| Noxopharm Limited | 2.4 Million AUD | 49.495% |
| PYC Therapeutics Limited | 22.05 Million AUD | 94.505% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 83.745% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 67.345% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -35.881% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 47.649% |
| CSL Limited | 22.41 Billion AUD | 99.995% |
| Arovella Therapeutics Limited | 17 Thousand AUD | -7030.918% |
| Bio-Gene Technology Limited | 18.32 Thousand AUD | -6517.118% |
| Clinuvel Pharmaceuticals Limited | 88.17 Million AUD | 98.625% |
| Starpharma Holdings Limited | 8.28 Million AUD | 85.375% |
| Nanollose Limited | 12.5 Thousand AUD | -9597.272% |
| Memphasys Limited | 60 Thousand AUD | -1920.427% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 4.45 Million AUD | 72.775% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -101.432% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 3.142% |
| Race Oncology Limited | 4 Million AUD | 69.72% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 496.65 Million AUD | 99.756% |
| Dimerix Limited | 583.47 Thousand AUD | -107.764% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 3.5 Million AUD | 65.421% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 89.465% |
| Alterity Therapeutics Limited | 4.01 Million AUD | 69.839% |
| BTC Health Limited | 16.36 Thousand AUD | -7309.878% |
| Acrux Limited | 5.09 Million AUD | 76.188% |
| Neuren Pharmaceuticals Limited | 231.92 Million AUD | 99.477% |
| Biotron Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | 152.24 Thousand AUD | -696.28% |
| AdAlta Limited | 1.73 Million AUD | 30.242% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -305.128% |
| Hexima Limited | - AUD | -Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | -163.307% |
| Paradigm Biopharmaceuticals Limited | 65.8 Thousand AUD | -1742.334% |
| Recce Pharmaceuticals Ltd | - AUD | -Infinity% |
| Avecho Biotechnology Limited | 473.55 Thousand AUD | -155.993% |
| Actinogen Medical Limited | 9.93 Million AUD | 87.794% |
| Immuron Limited | 4.9 Million AUD | 75.275% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 53.338% |